Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity.

Mouse studies indicated that plasma phospholipid transfer protein (PLTP) determines the plasma distribution of vitamin E, a potent lipophilic antioxidant. Vitamin E distribution, antioxidant status, and titer of anti-oxidized LDLs (oxLDL) autoantibodies were evaluated in plasma from control subjects (n = 31) and type 2 diabetic patients (n = 31) with elevated plasma PLTP concentration. Unlike diabetic and control HDLs, which displayed similar vitamin E contents, diabetic VLDLs and diabetic LDLs contained fewer vitamin E molecules than normal counterparts. Plasma PLTP concentration in diabetic plasmas correlated negatively with vitamin E in VLDL+LDL, but positively with vitamin E in HDL, with an even stronger correlation with the VLDL+LDL-to-HDL vitamin E ratio. Circulating levels of oxLDL were significantly higher in diabetic plasmas than in control plasmas. Whereas the titer of IgG autoantibodies to modified LDL did not differ significantly between diabetic patients and control subjects, diabetic plasmas showed significantly lower levels of potentially protective IgM autoantibodies. The present observations support a pathophysiological role of PLTP in decreasing the vitamin E content of apolipoprotein B-containing lipoproteins, but not of HDL in plasma of type 2 diabetic patients, contributing to a greater potential for LDL oxidation.

[1]  BengtVessby,et al.  Association of Type 2 Diabetes With Cyclooxygenase-Mediated Inflammation and Oxidative Stress in an Elderly Population , 2004 .

[2]  M. Jauhiainen,et al.  Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA Published, JLR Papers in Press, November 16, 2003. DOI 10.1194/jlr.D300023-JLR200 , 2004, Journal of Lipid Research.

[3]  M. Päivänsalo,et al.  Immunoglobulin M Type of Autoantibodies to Oxidized Low-Density Lipoprotein Has an Inverse Relation to Carotid Artery Atherosclerosis , 2003, Circulation.

[4]  R. Stocker,et al.  The role of vitamin E in atherosclerosis. , 2003, Progress in lipid research.

[5]  L. Lagrost,et al.  Increased Atherosclerotic Lesions in ApoE Mice With Plasma Phospholipid Transfer Protein Overexpression , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[6]  M. Jauhiainen,et al.  Human seminal plasma displays significant phospholipid transfer activity due to the presence of active phospholipid transfer protein. , 2003, Molecular human reproduction.

[7]  J. Witztum,et al.  Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL , 2003, Nature Medicine.

[8]  Joseph Juliano,et al.  Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[9]  F. Grosveld,et al.  Increased Risk of Atherosclerosis by Elevated Plasma Levels of Phospholipid Transfer Protein* , 2002, The Journal of Biological Chemistry.

[10]  J. Witztum,et al.  Innate and acquired immunity in atherogenesis , 2002, Nature Medicine.

[11]  E. Herrera,et al.  Dual effect of glucose on LDL oxidation: dependence on vitamin E. , 2002, Free radical biology & medicine.

[12]  M. Hanefeld,et al.  In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. , 2002, Diabetes.

[13]  A. Tall,et al.  Phospholipid Transfer Protein Deficiency Protects Circulating Lipoproteins from Oxidation Due to the Enhanced Accumulation of Vitamin E* , 2002, The Journal of Biological Chemistry.

[14]  D. Steinberg,et al.  Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis?: Do the Antioxidant Trials Conducted to Date Refute the Hypothesis? , 2002, Circulation.

[15]  D. Praticò.  Vitamin E: murine studies versus clinical trials. , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.

[16]  C. Napoli,et al.  Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. , 2001, European heart journal.

[17]  A. Tall,et al.  Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency , 2001, Nature Medicine.

[18]  J. Albers,et al.  Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. , 2001, Diabetes.

[19]  D. Steinberg,et al.  The oxidative modification hypothesis of atherosclerosis: does it hold for humans? , 2001, Trends in cardiovascular medicine.

[20]  Trevor A. Mori,et al.  Dietary Cosupplementation With Vitamin E and Coenzyme Q10 Inhibits Atherosclerosis in Apolipoprotein E Gene Knockout Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[21]  B. Fagerberg,et al.  Antibodies to Oxidized LDL in Relation to Intima-Media Thickness in Carotid and Femoral Arteries in 58-Year-Old Subjectively Clinically Healthy Men , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[22]  J. Witztum,et al.  Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Loyd,et al.  SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .

[24]  R. Wiklund,et al.  Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients , 2000 .

[25]  R. Klein,et al.  Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. , 2000, Diabetes.

[26]  B. Halliwell.  The antioxidant paradox , 2000, The Lancet.

[27]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[28]  W. Pryor.  Vitamin E and heart disease: basic science to clinical intervention trials. , 2000, Free radical biology & medicine.

[29]  P. Mecocci,et al.  Plasma levels of lipophilic antioxidants in very old patients with Type 2 diabetes , 2000, Diabetes/metabolism research and reviews.

[30]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[31]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[32]  P. Gambert,et al.  Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering α‐tocopherol to endothelial cells , 1999 .

[33]  BrunoVergès,et al.  Mass Concentration of Plasma Phospholipid Transfer Protein in Normolipidemic, Type IIa Hyperlipidemic, Type IIb Hyperlipidemic, and Non–Insulin-Dependent Diabetic Subjects as Measured by a Specific ELISA , 1999 .

[34]  R. Collins,et al.  MRC BHFHeart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience , 1999 .

[35]  J. Welch.  MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. , 1999, European heart journal.

[36]  D. Rader,et al.  Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice , 1998, Nature Medicine.

[37]  R. Dullaart,et al.  Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. , 1998, Atherosclerosis.

[38]  W. Sluiter,et al.  Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients , 1998, Diabetologia.

[39]  P. Gambert,et al.  Structure and function of the plasma phospholipid transfer protein. , 1998, Current opinion in lipidology.

[40]  J. Keaney,et al.  Antioxidants and atherosclerotic heart disease. , 1997, The New England journal of medicine.

[41]  W. Reitsma,et al.  Lowering of plasma phospholipid transfer protein activity by acute hyperglycaemia-induced hyperinsulinaemia in healthy men. , 1997, Scandinavian journal of clinical and laboratory investigation.

[42]  D. Herold,et al.  Effects of Vitamin E on Susceptibility of Low-Density Lipoprotein and Low-Density Lipoprotein Subfractions to Oxidation and on Protein Glycation in NIDDM , 1995, Diabetes Care.

[43]  M. Jauhiainen,et al.  Human plasma phospholipid transfer protein accelerates exchange/transfer of alpha-tocopherol between lipoproteins and cells. , 1995, The Biochemical journal.

[44]  G. Bellomo,et al.  Autoantibodies Against Oxidatively Modified Low-Density Lipoproteins in NIDDM , 1995, Diabetes.

[45]  V. Ord,et al.  ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[46]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[47]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[48]  A. Tall,et al.  Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. , 1985, Journal of lipid research.